US5750657A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions using fibrin monomer to make a fibrin sealant
Assignee: VIVOLUTION AS
•
Filing: 1993-10-18
•
Granted: 1998-05-12
•
Expires: 2013-10-18
Abstract
Abstract The subject invention relates to methods and compositions using nondynamic fibrin monomer which is selectively converted to a fibrin polymer which serves as the fibrin sealant.
Inventors
- 👤 Peter A. D. Edwardson
- 👤 John E. Fairbrother
- 👤 Ronald S. Gardner
- 👤 Derek A. Hollingsbee
- 👤 Stewart A. Cederholm-Williams
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 09:30
CPC Classifications
C; C12; C12N; C12N11/00; C12N11/02; C12N11/10; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/36; A61K38/363; A61K38/43; A61K38/45; A61K38/46; A61K38/48; A61K38/482; A61K38/4833; A61L; A61L15/00; A61L15/16; A61L15/22; A61L15/32; A61L17/00; A61L17/005; A61L24/00; A61L24/001; A61L24/0015; A61L24/04; A61L24/10; A61L24/106; A61L27/00; A61L27/14; A61L27/22; A61L27/225; A61P; A61P7/00; A61P7/04; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/75; C12N11/06; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/254; A61L2300/40; A61L2300/404; A61L2300/406; A61L2300/416; A61L2300/418; A61L2300/45
Claims Analysis
Total Claims: 55
Claim 1
Independent Claim
51 words
A method of making a fibrin sealant, which sealant comprises a fibrin polymer, comprising the steps of: (a) contacting a desired site with a composition which contains nondynamic fibrin monomer; and (b) converting said nondynamic fibrin monomer to a fibrin polymer concurrently with said contacting step, thereby forming a fibrin sealant.
Claim 2
Independent Claim
51 words
A method of making a fibrin sealant, which sealant comprises a fibrin polymer, comprising the steps of: (a) contacting a desired site with a composition which contains nondynamic fibrin monomer; and (b) converting said nondynamic fibrin monomer to a fibrin polymer concurrently with said contacting step, thereby forming a fibrin sealant.
Claim 3
Dependent Claim
26 words
The method of claim 1 wherein said fibrin monomer is selected from the group consisting of noncrosslinked fibrin I, des BB fibrin and noncrosslinked fibrin II.
Claim 4
Dependent Claim
12 words
The method of claim 2 wherein said fibrin monomer is fibrin I.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein said fibrin polymer is fibrin II polymer.
Claim 6
Dependent Claim
11 words
The method of claim 1 wherein said fibrin polymer is crosslinked.
Claim 7
Dependent Claim
27 words
The method of claim 1 wherein the composition containing nondynamic fibrin monomer is substantially free of any exogenous enzyme which catalyzes the formation of fibrin from fibrinogen.
Claim 8
Dependent Claim
28 words
The method of claim 1 wherein said composition is formed from a source selected from the group consisting of blood, recombinant fibrinogen and cell cultures that secrete fibrinogen.
Claim 9
Dependent Claim
10 words
The method of claim 7 wherein said source is blood.
Claim 10
Dependent Claim
21 words
The method of claim 8 wherein the composition containing nondynamic fibrin monomer further comprises prothrombin, activators of prothrombin and factor XIII.
Claim 11
Dependent Claim
11 words
The method of claim 7 wherein said blood is autologous blood.
Claim 12
Dependent Claim
27 words
The method of claim 1 wherein said rendering step is carried out by means of an alkaline buffer or distilled water being added to said fibrin monomer.
Claim 13
Dependent Claim
19 words
The method of claim 11 wherein said alkaline buffer or distilled water further comprises a source of calcium ions.
Claim 14
Dependent Claim
38 words
The method of claim 11 wherein said alkaline buffer is selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide, bicarbonate buffers, tri-metal salts of citric acid, salts of acetic acid and salts of sulfuric acid.
Claim 15
Dependent Claim
74 words
The method of claim 11 wherein said alkaline buffer is selected from the group consisting of 0.5-0.75M Sodium carbonate/bicarbonate pH 10-10.5, 0.5-0.75M Sodium bicarbonate/NaOH pH 10.0, 1.5M Glycine/NaOH pH 10.0, 0.5-1.0M Bis hydroxyethylaminoethane sulphonic acid (BES) pH 7.5, 1M Hydroxyethylpiperazine propane sulphonic acid (EPPS) pH 8.5, 0.5M Tricine pH 8.5, 1M Morpholino propane sulphonic acid (MOPS) pH 8.0, 1M Trishydoroxymethyl aminoethane sulphonic acid (TES) pH 8.0 and 0.5M Cyclohexylaminoethane sulphonic acid (CHES) pH 10.0.
Claim 16
Dependent Claim
46 words
The method of claim 11 wherein said alkaline buffer is selected from the group consisting of 0.5-0.75M Sodium carbonate/bicarbonate pH 10-10.5, 0.5-1.0M Bis hydroxeythylaminoethane sulphonic acid (BES) pH 7.5, 1M Hydroxyethylpiperazine propane sulphonic acid (EPPS) pH 8.5 and 1M Trishydroxymethyl aminoethane sulphonic acid (TES) pH 8.0.
Claim 17
Dependent Claim
35 words
The method of claim 11 wherein said contacting step is carried out by means of a double-barrelled syringe, wherein one barrel contains said composition and the other barrel contains said alkaline buffer or distilled water.
Claim 18
Dependent Claim
38 words
The method of claim 1 wherein said composition is an aqueous composition wherein said aqueous composition further comprises (a) an acid buffer that has a pH of from about 1 to about 5 or (b) a chaotropic agent.
Claim 19
Dependent Claim
77 words
The method of claim 17 wherein said acid buffer is selected from the group consisting of acetic acid, salts of acetic acid, succinic acid, salts of succinic acid, glucuronic acid, salts of glucuronic acid, cysteic acid, salts of cysteic acid, crotonic acid, salts of crotonic acid itaconic acid, salts of itaconic acid, glutamic acid, salts of glutamic acid, formic acid, salts of formic acid, aspartic acid, salts of aspartic acid, adipic acid, and salts of adipic acid.
Claim 20
Dependent Claim
27 words
The method of claim 18 wherein said acid buffer is selected from the group consisting of succinic acid, aspartic acid, adipic acid and salts of acetic acid.
Claim 21
Dependent Claim
12 words
The method of claim 19 wherein said acid buffer is sodium acetate.
Claim 22
Dependent Claim
19 words
The method of claim 18 wherein the concentration of said acid buffer is from about 0.02M to about 1M.
Claim 23
Dependent Claim
15 words
The method of claim 21 wherein said concentration is from about 0.1M to about 0.3M.
Claim 24
Dependent Claim
27 words
The method of claim 17 wherein said chaotropic agent is selected from the group consisting of urea, sodium bromide, guanidine hydrochloride, KCNS, potassium iodide and potassium bromide.
Claim 25
Dependent Claim
19 words
The method of claim 23 wherein the concentration of said chaotropic agent is from about 0.2M to about 6.0M.
Claim 26
Dependent Claim
15 words
The method of claim 24 wherein said concentration is from about 3.5M to about 5.0M.
Claim 27
Dependent Claim
24 words
The method of claim 17 wherein the concentration of fibrin monomer in said aqueous solution is from about 10 mg/ml to about 200 mg/ml.
Claim 28
Dependent Claim
17 words
The method of claim 26 wherein said concentration is from about 20 mg/ml to about 100 mg/ml.
Claim 29
Dependent Claim
16 words
The method of claim 17 wherein said aqueous composition further comprises a source of calcium ions.
Claim 30
Dependent Claim
13 words
The method of claim 1 wherein the desired site is on a mammal.
Claim 31
Dependent Claim
11 words
The method of claim 29 wherein said mammal is a human.
Claim 32
Dependent Claim
40 words
The method of claim 30 wherein the desired site is selected from the group consisting of skin, cardiovascular system, lymphatic system, pulmonary system, ear, nose, throat, eye, liver, spleen, cranial, spinal, maxillo-facial, bone, tendon, pancreas, genito-urinary tract and alimentary tract.
Claim 33
Independent Claim
45 words
A method of making a fibrin sealant which comprises: (a) contacting a desired site with a composition which contains nondynamic noncrosslinked fibrin; and (b) rendering said noncrosslinked fibrin dynamic concurrently with said contacting step such that said noncrosslinked fibrin is converted to said fibrin sealant.
Claim 34
Independent Claim
45 words
A method of making a fibrin sealant which comprises: (a) contacting a desired site with a composition which contains nondynamic noncrosslinked fibrin; and (b) rendering said noncrosslinked fibrin dynamic concurrently with said contacting step such that said noncrosslinked fibrin is converted to said fibrin sealant.
Claim 35
Dependent Claim
26 words
The method of claim 32 wherein said noncrosslinked fibrin is selected from the group consisting of noncrosslinked fibrin I, des BB fibrin and noncrosslinked fibrin II.
Claim 36
Dependent Claim
12 words
The method of claim 33 wherein said noncrosslinked fibrin is fibrin I.
Claim 37
Dependent Claim
19 words
The method of claim 32 wherein said composition is formed from blood, recombinant fibrinogen and cells that secrete fibrinogen.
Claim 38
Dependent Claim
11 words
The method of claim 35 wherein said blood is autologous blood.
Claim 39
Dependent Claim
22 words
The method of claim 32 wherein said rendering step is carried out by contacting said composition with a source of calcium ions.
Claim 40
Dependent Claim
38 words
An aqueous composition comprising noncrosslinked fibrin monomer wherein the concentration of said fibrin monomer is greater than 10 mg/ml and up to about 200 mg/ml and said composition has a pH of from about 1 to about 5.
Claim 41
Dependent Claim
38 words
An aqueous composition comprising noncrosslinked fibrin monomer wherein the concentration of said fibrin monomer is greater than 10 mg/ml and up to about 200 mg/ml and said composition has a pH of from about 1 to about 5.
Claim 42
Dependent Claim
18 words
The aqueous composition of claim 38 wherein said concentration is from about 20 mg/ml to about 100 mg/ml.
Claim 43
Dependent Claim
25 words
The aqueous composition of claim 38 wherein said fibrin monomer is selected from the group consisting of fibrin I, des BB fibrin and fibrin II.
Claim 44
Dependent Claim
13 words
The aqueous composition of claim 40 wherein said fibrin monomer is fibrin I.
Claim 45
Dependent Claim
22 words
An aqueous composition comprising fibrin monomer wherein the concentration of said fibrin monomer is from about 20 mg/ml to about 200 mg/ml.
Claim 46
Dependent Claim
22 words
An aqueous composition comprising fibrin monomer wherein the concentration of said fibrin monomer is from about 20 mg/ml to about 200 mg/ml.
Claim 47
Dependent Claim
18 words
The aqueous composition of claim 42 wherein said concentration is from about 20 mg/ml to about 100 mg/ml.
Claim 48
Dependent Claim
25 words
The aqueous composition of claim 42 wherein said fibrin monomer is selected from the group consisting of fibrin I, des BB fibrin and fibrin II.
Claim 49
Dependent Claim
13 words
The aqueous composition of claim 44 wherein said fibrin monomer is fibrin I.
Claim 50
Dependent Claim
47 words
An aqueous composition substantially free of an exogenous enzyme which catalyzes the cleavage of fibrinopeptides A and/or B from fibrinogen comprising: (a) fibrin monomer, and (b) a source of calcium ions, wherein the concentration of said calcium ions is from about 5 mM to about 200 mM.
Claim 51
Dependent Claim
47 words
An aqueous composition substantially free of an exogenous enzyme which catalyzes the cleavage of fibrinopeptides A and/or B from fibrinogen comprising: (a) fibrin monomer, and (b) a source of calcium ions, wherein the concentration of said calcium ions is from about 5 mM to about 200 mM.
Claim 52
Dependent Claim
102 words
In a method of preparing a fibrin sealant comprising a fibrin polymer for application to a desired site, which method comprises: subjecting a source of fibrinogen to an enzyme which catalyzes the cleavage of fibrinopeptide A and/or B from fibrinogen; providing conditions to cause the polymerization of the so-treated source of fibrinogen thereby forming said fibrin polymer; the improvement comprising: subjecting said source of fibrinogen to said enzyme prior to application to said desired site and thereafter applying the so-treated source of fibrinogen, substantially free of said enzyme, to said desired site under conditions to cause said polymerization to said fibrin polymer.
Claim 53
Dependent Claim
102 words
In a method of preparing a fibrin sealant comprising a fibrin polymer for application to a desired site, which method comprises: subjecting a source of fibrinogen to an enzyme which catalyzes the cleavage of fibrinopeptide A and/or B from fibrinogen; providing conditions to cause the polymerization of the so-treated source of fibrinogen thereby forming said fibrin polymer; the improvement comprising: subjecting said source of fibrinogen to said enzyme prior to application to said desired site and thereafter applying the so-treated source of fibrinogen, substantially free of said enzyme, to said desired site under conditions to cause said polymerization to said fibrin polymer.
Claim 54
Independent Claim
95 words
A method of making a fibrin sealant for application to a single patient, which sealant comprises a fibrin polymer, comprising the steps of subjecting a source of fibrinogen to an enzyme capable of catalyzing the cleavage of fibrinopeptide A and/or B from fibrinogen, which enzyme is exogenous to said patient; substantially separating said enzyme from the so-treated source of fibrinogen; and applying the so-treated fibrinogen to said patient under conditions to provide for the polymerization of the so-treated fibrinogen to a fibrin polymer whereby a fibrin sealant substantially free of said exogenous enzyme is provided.
Claim 55
Independent Claim
95 words
A method of making a fibrin sealant for application to a single patient, which sealant comprises a fibrin polymer, comprising the steps of subjecting a source of fibrinogen to an enzyme capable of catalyzing the cleavage of fibrinopeptide A and/or B from fibrinogen, which enzyme is exogenous to said patient; substantially separating said enzyme from the so-treated source of fibrinogen; and applying the so-treated fibrinogen to said patient under conditions to provide for the polymerization of the so-treated fibrinogen to a fibrin polymer whereby a fibrin sealant substantially free of said exogenous enzyme is provided.
References Cited (Backward Citations)
US2533004A
Cited
US3849252A
Cited
US4167823A
Cited
US4295855A
Cited
US4377572A
Cited
US4298598A
Cited
US4480029A
Cited
US4495278A
Cited
EP0068149A2
Cited
US4427650A
Cited
US4427651A
Cited
US4442655A
Cited
US4438198A
Cited
DE3230849A1
Cited
WO1986001814A1
Cited
US4928603A
Cited
US4627879A
Cited
US4957903A
Cited
US5407671A
Cited
US4714457A
Cited
US5318782A
Cited
WO1988002259A1
Cited
US5151412A
Cited
US4709037A
Cited
US5175087A
Cited
US5047506A
Cited
US5290552A
Cited
US4909251A
Cited
WO1990004786A1
Cited
JPH02129224A
Cited
US5026785A
Cited
EP0423938B1
Cited
US5252743A
Cited
US5030215A
Cited
WO1991009573A1
Cited
WO1991009641A1
Cited
US5185001A
Cited
US5180828A
Cited
EP0472205A1
Cited
WO1992015341A1
Cited
EP0534178A2
Cited
US5527692A
Cited
WO1993019805A1
Cited
US5272074A
Cited
US5324647A
Cited
EP0592242A1
Cited
US5330974A
Cited
US5464471A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-05-11 | 2001-11-10 | 2002-05-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-05-11 | 2005-11-10 | 2006-05-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-05-11 | 2009-11-10 | 2010-05-12 | $7700.00 | Window Closed / Lapsed |